Regeneron Pharmaceuticals announced Tuesday that its COVID-19 antibody treatment has proven in a clinical study to sharply reduce the risk of hospitalization or death among patients who test positive for the virus.
Trending:
Regeneron antibody drug cuts COVID-19 death risk by 70 percent